Search | Clinical Trials Finder

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization, Child, Hospitalized
Interventions: Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Cooperstown, New York • New York, New York

Conditions: HIV Infection
Interventions: Maraviroc, Emtricitabine, Tenofovir disoproxil fumarate, Maraviroc placebo, Emtricitabine placebo, Tenofovir disoproxil fumarate placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Adherence, Substance Abuse
Interventions: PM Component Text Reminders; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 16 Years to 29 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: La Jolla, California • Detroit, Michigan

Conditions: Pulmonary Artery Hypertension
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV, Depression, Posttraumatic Stress Disorder
Interventions: Enhanced Sexual Health Intervention for Men (ES-HIM), Health Promotion (HP) Comparison Arm; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Male only
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Inglewood, California • Los Angeles, California

Conditions: HIV-1 Infection
Interventions: Islatravir, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Hollywood, Florida • Baltimore, Maryland • Lincoln, Nebraska + 1 more

Conditions: HIV Infections
Interventions: Behavioral counseling, HIV-1 Antibody Test Kit; Other · Device
Lead sponsor: bioLytical Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 14
States / cities: Los Angeles, California • Palm Springs, California • San Diego, California + 8 more

Conditions: HIV Infections
Interventions: CD4 Antigens; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: San Francisco, California • Stanford, California • Chicago, Illinois + 2 more

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Peer-oriented intervention, Group cognitive behavioral therapy (CBT); Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 74 Years
Enrollment: 746 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV/AIDS
Interventions: BCAP peer-driven intervention (PDI), Control intervention; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 3,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Prevention
Interventions: Value Affirmation and Future Selves Combination, Control writing exercise; Behavioral
Lead sponsor: Stuart Fisk; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Interventions: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs); Biological
Lead sponsor: Atara Biotherapeutics; Industry
Eligibility: Not listed
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV, HIV Testing, Women, Contingency Management
Interventions: Standard referral for HIV testing, Online risk reduction training, Reinforcement; Behavioral
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Alcohol; Harmful Use, Binge Drinking, Risk Behavior, HIV Infection
Interventions: Computerized brief alcohol intervention + IVR booster calls, Computerized brief alcohol intervention, Attention Control; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 439 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV-infection/AIDS
Interventions: Cultural adaptation of a patient-provider communication tool; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Stage III High Grade B-Cell Lymphoma, Stage IV High Grade B-Cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma, Intravascular Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma of Breast, Diffuse Large B Cell Lymphoma of Testis, HIV-associated Diffuse Large B Cell Lymphoma, Double Expressor DLBCL
Interventions: Cerebral Spinal Fluid ctDNA; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: HIV Prevention, PrEP
Interventions: Using PrEP, Doing it for Ourselves (UPDOs), Standard of Care; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Bisexually-active Men, at Risk for HIV
Interventions: RISE life coaching intervention, HIV Counseling; Behavioral
Lead sponsor: Public Health Management Corporation; Other
Eligibility: 18 Years and older · Male only
Enrollment: 169 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV, Substance Abuse
Interventions: Young Women's Health CoOp (YWHC), HIV Counseling/Testing; Behavioral
Lead sponsor: RTI International; Other
Eligibility: 16 Years to 21 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C
Interventions: Suboxone, Truvada, Mavyret; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Durham, North Carolina • Greensboro, North Carolina

Conditions: HIV Preexposure Prophylaxis
Interventions: ISL, FTC/TDF, FTC/TAF, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more

Conditions: HIV, Substance Use
Interventions: Alcohol Use BI, Nutrition Intervention; Behavioral
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 16 Years to 25 Years
Enrollment: 464 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Pre-exposure Prophylaxis, HIV-1-infection
Interventions: Peer Navigation; Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

A Test of Behavioral Intervention for Women at High Risk for HIV Infection

Targeting PM to Improve HIV Adherence in Adolescents at Risk for Substance Abuse

Vascular Subphenotypes of Lung Disease in HIV & COPD

An HIV Intervention for Black Men at Risk - The Enhanced Sexual Health Intervention for Men (ES-HIM)

Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection

A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs

Peer-driven Intervention to Seek, Test & Treat Heterosexuals at High Risk for HIV

Scalable Interventions to Increase PrEP Adherence: Value Affirmation and Future Selves

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

A Reinforcement Intervention for Increasing HIV Testing Among At-Risk Women

Computerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women

WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

Using PrEP, Doing It for Ourselves

Evaluation of a New HIV Prevention Intervention for Black Bisexually-active Men

Young Women's Health CoOp (Cooperative) in Cape Town

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

Employing eSBI in HIV Testing for At-risk Youth

Peer Outreach and Navigation Intervention to Increase PrEP Uptake Among Women at High Risk for HIV